204 related articles for article (PubMed ID: 16544979)
21. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction.
Wada T; Jagadeesh GJ; Nelson DL; Candotti F
Hum Gene Ther; 2002 Jun; 13(9):1039-46. PubMed ID: 12067437
[TBL] [Abstract][Full Text] [Related]
22. Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
Galy A; Roncarolo MG; Thrasher AJ
Expert Opin Biol Ther; 2008 Feb; 8(2):181-90. PubMed ID: 18194074
[TBL] [Abstract][Full Text] [Related]
23. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells.
Strom TS; Turner SJ; Andreansky S; Liu H; Doherty PC; Srivastava DK; Cunningham JM; Nienhuis AW
Blood; 2003 Nov; 102(9):3108-16. PubMed ID: 12855574
[TBL] [Abstract][Full Text] [Related]
24. A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding.
Massaad MJ; Ramesh N; Le Bras S; Giliani S; Notarangelo LD; Al-Herz W; Notarangelo LD; Geha RS
J Allergy Clin Immunol; 2011 Apr; 127(4):998-1005.e1-2. PubMed ID: 21376381
[TBL] [Abstract][Full Text] [Related]
25. Was cDNA sequences modulate transgene expression of was promoter-driven lentiviral vectors.
Toscano MG; Benabdellah K; Muñoz P; Frecha C; Cobo M; Martín F
Hum Gene Ther; 2009 Nov; 20(11):1279-90. PubMed ID: 19630517
[TBL] [Abstract][Full Text] [Related]
26. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome.
Rai R; Romito M; Rivers E; Turchiano G; Blattner G; Vetharoy W; Ladon D; Andrieux G; Zhang F; Zinicola M; Leon-Rico D; Santilli G; Thrasher AJ; Cavazza A
Nat Commun; 2020 Aug; 11(1):4034. PubMed ID: 32788576
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.
Braun CJ; Boztug K; Paruzynski A; Witzel M; Schwarzer A; Rothe M; Modlich U; Beier R; Göhring G; Steinemann D; Fronza R; Ball CR; Haemmerle R; Naundorf S; Kühlcke K; Rose M; Fraser C; Mathias L; Ferrari R; Abboud MR; Al-Herz W; Kondratenko I; Maródi L; Glimm H; Schlegelberger B; Schambach A; Albert MH; Schmidt M; von Kalle C; Klein C
Sci Transl Med; 2014 Mar; 6(227):227ra33. PubMed ID: 24622513
[TBL] [Abstract][Full Text] [Related]
28. WASP and the phenotypic range associated with deficiency.
Notarangelo LD; Notarangelo LD; Ochs HD
Curr Opin Allergy Clin Immunol; 2005 Dec; 5(6):485-90. PubMed ID: 16264326
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Labrosse R; Chu JI; Armant MA; Everett JK; Pellin D; Kareddy N; Frelinger AL; Henderson LA; O'Connell AE; Biswas A; Coenen-van der Spek J; Miggelbrink A; Fiorini C; Adhikari H; Berry CC; Cantu VA; Fong J; Jaroslavsky J; Karadeniz DF; Li QZ; Reddy S; Roche AM; Zhu C; Whangbo JS; Dansereau C; Mackinnon B; Morris E; Koo SM; London WB; Baris S; Ozen A; Karakoc-Aydiner E; Despotovic JM; Forbes Satter LR; Saitoh A; Aizawa Y; King A; Nguyen MAT; Vu VDU; Snapper SB; Galy A; Notarangelo LD; Bushman FD; Williams DA; Pai SY
Blood; 2023 Oct; 142(15):1281-1296. PubMed ID: 37478401
[TBL] [Abstract][Full Text] [Related]
31. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Boztug K; Dewey RA; Klein C
Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
[TBL] [Abstract][Full Text] [Related]
32. Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations.
Candotti F; Facchetti F; Blanzuoli L; Stewart DM; Nelson DL; Blaese RM
Gene Ther; 1999 Jun; 6(6):1170-4. PubMed ID: 10455421
[TBL] [Abstract][Full Text] [Related]
33. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein.
Strom TS; Gabbard W; Kelly PF; Cunningham JM; Nienhuis AW
Gene Ther; 2003 May; 10(9):803-9. PubMed ID: 12704420
[TBL] [Abstract][Full Text] [Related]
34. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins.
Huang MM; Tsuboi S; Wong A; Yu XJ; Oh-Eda M; Derry JM; Francke U; Fukuda M; Weinberg KI; Kohn DB
Gene Ther; 2000 Feb; 7(4):314-20. PubMed ID: 10694812
[TBL] [Abstract][Full Text] [Related]
35. Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients.
Pala F; Morbach H; Castiello MC; Schickel JN; Scaramuzza S; Chamberlain N; Cassani B; Glauzy S; Romberg N; Candotti F; Aiuti A; Bosticardo M; Villa A; Meffre E
J Clin Invest; 2015 Oct; 125(10):3941-51. PubMed ID: 26368308
[TBL] [Abstract][Full Text] [Related]
36. Current and emerging treatment options for Wiskott-Aldrich syndrome.
Worth AJ; Thrasher AJ
Expert Rev Clin Immunol; 2015; 11(9):1015-32. PubMed ID: 26159751
[TBL] [Abstract][Full Text] [Related]
37. Wiskott-Aldrich Syndrome in four male siblings from a consanguineous family from Lebanon.
Mansour R; El-Orfali Y; Saber A; Noun D; Youssef N; Youssef Y; Hanna-Wakim R; Dbaibo G; Abboud M; Massaad MJ
Clin Immunol; 2020 Oct; 219():108573. PubMed ID: 32814211
[TBL] [Abstract][Full Text] [Related]
38. A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors.
Ariga T
Expert Rev Clin Immunol; 2013 Nov; 9(11):1015-8. PubMed ID: 24168409
[TBL] [Abstract][Full Text] [Related]
39. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.
Scaramuzza S; Biasco L; Ripamonti A; Castiello MC; Loperfido M; Draghici E; Hernandez RJ; Benedicenti F; Radrizzani M; Salomoni M; Ranzani M; Bartholomae CC; Vicenzi E; Finocchi A; Bredius R; Bosticardo M; Schmidt M; von Kalle C; Montini E; Biffi A; Roncarolo MG; Naldini L; Villa A; Aiuti A
Mol Ther; 2013 Jan; 21(1):175-84. PubMed ID: 22371846
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.
Magnani A; Semeraro M; Adam F; Booth C; Dupré L; Morris EC; Gabrion A; Roudaut C; Borgel D; Toubert A; Clave E; Abdo C; Gorochov G; Petermann R; Guiot M; Miyara M; Moshous D; Magrin E; Denis A; Suarez F; Lagresle C; Roche AM; Everett J; Trinquand A; Guisset M; Bayford JX; Hacein-Bey-Abina S; Kauskot A; Elfeky R; Rivat C; Abbas S; Gaspar HB; Macintyre E; Picard C; Bushman FD; Galy A; Fischer A; Six E; Thrasher AJ; Cavazzana M
Nat Med; 2022 Jan; 28(1):71-80. PubMed ID: 35075289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
